Castleark Management’s CONMED CNMD Stock Holding History

Castleark Management’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-57,450	Closed	-$8.53M	–	314
2022 Q1	$8.53M	Buy	+57,450	New	+$8.02M	0.37%	59
2021 Q3	–	Sell	-78,442	Closed	-$10.8M	–	341
2021 Q2	$10.8M	Sell	78,442 -4,960	-6%	-$679K	0.36%	70
2021 Q1	$10.9M	Buy	83,402 +28,350	+51%	+$3.41M	0.39%	77
2020 Q4	$6.17M	Buy	+55,052	New	+$5.21M	0.23%	120
2020 Q1	–	Sell	-94,702	Closed	-$10.6M	–	344
2019 Q4	$10.6M	Sell	94,702 -12,954	-12%	-$1.38M	0.42%	63
2019 Q3	$10.4M	Buy	+107,656	New	+$10.1M	0.42%	78
2018 Q4	–	Sell	-121,045	Closed	-$9.59M	–	375
2018 Q3	$9.59M	Sell	121,045 -1,880	-2%	-$145K	0.28%	126
2018 Q2	$9M	Buy	122,925 +17,080	+16%	+$1.16M	0.28%	118
2018 Q1	$6.7M	Buy	+105,845	New	+$6.32M	0.21%	143
2015 Q3	–	Sell	-109,400	Closed	-$6.38M	–	372
2015 Q2	$6.38M	Buy	+109,400	New	+$5.9M	0.17%	162

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Castleark Management's CNMD Position: Q2 2022 in Review

Castleark Management sold out of CONMED (CNMD) in Q2 2022, closing a stake of 57,450 shares — an estimated $8.53M sold.

Castleark Management first reported a position in CNMD in Q2 2015 and held it in 10 quarters. The position peaked at $10.9M in Q1 2021. 280 funds tracked by Wall St. Rank hold CNMD as of Q2 2022.

Castleark Management reported no remaining CONMED position as of Q2 2022 after selling out during the quarter.
Castleark Management sold 57,450 CONMED shares in Q2 2022, an estimated $8.53M.
Castleark Management first reported a position in CONMED in Q2 2015 and held it in 10 quarters.
Castleark Management's CONMED position peaked at $10.9M in Q1 2021.
280 funds tracked by Wall St. Rank held CONMED as of Q2 2022.

Based on Castleark Management's 13F filing for Q2 2022, filed 16 Aug 2022.